Pharmaceuticals

Rituximab Biosimilars Sector Forecast Shows Robust Momentum, Climbing to $6.26 Billion With 13% CAGR

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the rituximab biosimilars market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Rituximab Biosimilars Market expected to reach by 2030?

The rituximab biosimilars market has experienced significant expansion recently. This market is projected to expand from $3.42 billion in 2025 to $3.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. Historically, this growth has been driven by factors such as the high cost of originator rituximab, the increasing prevalence of non-hodgkin’s lymphoma, the growing incidence of chronic lymphocytic leukemia, a rising awareness regarding autoimmune disease management, and restricted access to advanced biologics.

The rituximab biosimilars market is projected to experience swift expansion over the coming years. This market is forecast to reach $6.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. Key factors driving this growth during the projection period include the introduction of novel biosimilar formulations, wider availability of subcutaneous administration methods, increased uptake in developing economies, enhanced governmental and insurance backing for biosimilars, and their incorporation into hospital and specialized pharmacy initiatives. Noteworthy trends anticipated in the forecast period encompass the increasing utilization of rituximab biosimilars in treating oncology and autoimmune conditions, the broadened application of subcutaneous and pre-filled delivery systems, a rising inclination towards economical monoclonal antibody substitutes, greater deployment of antibody-drug conjugates (ADCs) in precision therapies, and improved distribution networks through hospitals and retail pharmacies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp

What Drivers Are Driving Adoption Within The Rituximab Biosimilars Market?

The increasing occurrence of non-Hodgkin’s lymphoma (NHL) is projected to boost the expansion of the rituximab biosimilars market in the future. Non-Hodgkin’s lymphoma is a cancer originating in lymphocytes, a type of white blood cell essential to the body’s immune system. Its increased prevalence is driven by higher incidence rates, especially among older demographics and from lifestyle and environmental influences. Rituximab biosimilars effectively target and eliminate CD20-positive B cells, which helps to diminish tumor size, enhance immune system control, and offer a more accessible and economical treatment choice for individuals with non-Hodgkin’s lymphoma (NHL), leading to better overall treatment results and an improved quality of life. For example, in January 2024, data from the American Cancer Society, a US-based cancer advocacy group, indicated that roughly 80,620 people (comprising 44,590 men and 36,030 women) were anticipated to be diagnosed with non-Hodgkin lymphoma. Furthermore, an estimated 20,140 deaths (with 11,780 men and 8,360 women) were projected, and the lifetime probability of developing this cancer stood at approximately 1 in 42 for men and 1 in 52 for women. Consequently, the increasing prevalence of non-Hodgkin’s lymphoma is fueling the expansion of the rituximab biosimilars market.

How Is The Rituximab Biosimilars Market Organized Into Various Segments?

The rituximab biosimilars market covered in this report is segmented –

1) By Route Of Administration: Subcutaneous, Intravenous

2) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Mail Order

Subsegments:

1) By Subcutaneous: Pre-filled Syringes, Injection Pens

2) By Intravenous: IV Infusion Solutions, IV Push Formulations

What Long-Term Trends Are Expected To Shape The Future Of The Rituximab Biosimilars Market?

Leading companies in the rituximab biosimilars market are concentrating on developing innovative products through strategic collaborations. This strategy aims to improve accessibility and offer more affordable treatment solutions for patients dealing with various immunological and oncological conditions. Partnering with established entities helps companies expedite commercialization, combine expertise in regulatory approvals and distribution, and effectively launch biosimilars, consequently enhancing patient access and market penetration. An example occurred in July 2023, when Dr. Reddy’s Laboratories partnered with Fresenius Kabi to commercialize their prospective rituximab biosimilar in the US. This partnership intends to introduce a biosimilar form of rituximab to the market, thereby providing a more economical and available treatment option for patients. The presence of a rituximab biosimilar in the United States could significantly expand access to this vital treatment for patients suffering from conditions such as rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Who Are The Major Companies Operating In The Rituximab Biosimilars Market?

Major companies operating in the rituximab biosimilars market are Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy’s Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, Celltrion, Biocad, MABION S.A., Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Rituximab Biosimilars Market?

North America was the largest region in the rituximab biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rituximab Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3430&type=smp

Browse Through More Reports Similar to the Global Rituximab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795